🇺🇸 FDA
Pipeline program

TAK-186

CP-MVC-101-01

Phase 2 small_molecule terminated

Quick answer

TAK-186 for Squamous Cell Cancer of Head and Neck (SCCHN) is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Squamous Cell Cancer of Head and Neck (SCCHN)
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials